Not Yet RecruitingPhase 2ketamine
Quelling of Excitotoxicity in Acute Stroke With Ketamine
Sponsored by Lower Merion Neurology Research Foundation
NCT ID
NCT03223220
Target Enrollment
120 participants
Start Date
2024-07-01
Est. Completion
2027-12-31
About This Study
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.
Conditions Studied
Interventions
- •Ketamine
- •Normal Saline
- •Midazolam injection
Eligibility
Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: 1. All patients who are 18 years or older, presenting or admitted to the study site with acute ischemic stroke, up to 24 hours since their last known well time 2. An MRI evidence of acute ischemic infarct on the diffusion-weighted imaging with ADC correlate 3. Pre-stroke modified Rankin scale of 0-2 4. Patient should be willing to participate in the study by providing a written consent himself/herself or through a proxy. Exclusion Criteria: 1. Eligibility to receive IV Alteplase or intra-arterial thrombectomy/embolectomy 2. Longer than 24 hours since last known well time 3. Pre-stroke modified Rankin scale of 3 or above. 4. Pregnant or lactating females 5. Pre-existing psychiatric illness 6. Intracranial hemorrhage of any type at presentation 7. Seizure at onset of symptoms 8. Sustained uncontrolled hypertension defined as Systolic Blood pressure greater than 185 mmHg or Diastolic Blood Pressure greater than 110 mmHg, despite administration of antihypertensive medications 9. Known hypersensitivity or adverse reaction to prior administration of Ketamine 10. Inability/refusal to provide consent by the patient or through a proxy
Study Locations (1)
Lankenau Medical Center
Wynnewood, Pennsylvania, United States